Quoin Pharmaceuticals Receives FDA Clearance for New Study

Quoin Pharmaceuticals ( (QNRX) ) has shared an update.

On May 22, 2025, Quoin Pharmaceuticals announced it received FDA clearance to initiate a second pivotal clinical study for its lead product, QRX003, aimed at treating Netherton Syndrome. This study, CL-QRX003-002, will test QRX003 in conjunction with off-label systemic therapy and complements another ongoing study where QRX003 is used as monotherapy. The combined data from these studies is expected to provide a comprehensive safety and efficacy profile, potentially supporting regulatory approval. Quoin plans to complete recruitment by the end of Q1 2026 and file for regulatory approval later that year, with the studies involving multiple U.S. and international sites.

The most recent analyst rating on (QNRX) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. Their innovative pipeline includes products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.

Average Trading Volume: 361,865

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.98M

For an in-depth examination of QNRX stock, go to TipRanks’ Stock Analysis page.